Renerva Implants First PNM-CAP Device for Neuroma Pain
PITTSBURGH, May 13, 2026 Renerva, Inc. announced the successful first-in-human implantation of its investigational PNM-CAP™ device, marking a major...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PITTSBURGH, May 13, 2026 Renerva, Inc. announced the successful first-in-human implantation of its investigational PNM-CAP™ device, marking a major...
NORTHBROOK, Ill., May 12, 2026 Astellas Pharma US announced new clinical findings showing that IZERVAY® (avacincaptad pegol intravitreal solution)...
